SUBSCRIBE
SUBSCRIBE
News   Drug Development

Targeted Use of OSI Pharmaceuticals, Inc.'s Tarceva Effective for Some Tumors

September 15, 2008 | 
1 min read
LONDON, Sept 13 (Reuters) - Using OSI Pharmaceuticals Inc's Tarceva pill to target tumours carrying specific genetic mutations significantly extended the lives of some people with lung cancer, Spanish researchers said on Saturday.
Clinical research Postmarket research Europe
MORE ON THIS TOPIC
Pictured: Roche tower in Basel, Switzerland
Manufacturing
Roche Seeks Antibiotic Partner as Rising Manufacturing Costs Drive Supply Rethink
February 24, 2026
 · 
1 min read
 · 
Nick Paul Taylor
Novo Nordisk advertising flags and logo on facade
Drug pricing
Novo Slashes GLP-1 Prices Again, Touts New Weight Loss Data on Heels of Lilly Loss
February 24, 2026
 · 
3 min read
 · 
Jef Akst
Business and financial crisis vector concept with businessman falling down the hole. Symbol of market crash, recession, risk, bankruptcy and loss. Eps10 illustration.
Cardiovascular disease
Gossamer Nosedives as Late-Stage Failure Plunges PAH Program Into Uncertainty
February 24, 2026
 · 
2 min read
 · 
Tristan Manalac
Illustration of man walking in the beach between two blue seas, surreal abstract path concept
Rare disease
FDA’s Bespoke Pathway To Focus on Gene Editing and RNA-Based Treatments for Rare Diseases
February 23, 2026
 · 
3 min read
 · 
Nick Paul Taylor